You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科濟藥業-B(2171.HK)暗盤大幅收跌近14%
格隆匯 06-17 18:38
格隆匯6月17日丨據富途證券,科濟藥業-B(2171.HK)暗盤持續走低,收報28.3港元,較發行價32.8港元跌13.72%,成交7796萬港元,總市值160.56億港元。此次上市發行9474.7萬股,每手500股,一手中籤率5%,香港公開發售獲超購433.57倍,淨籌29.4億港元。科濟藥業是CAR-T細胞療法領域的領導者之一,該公司是世界上第一個成功識別、驗證和報吿Claudin18.2(或CLDN18.2)和glypican-3(或GPC3)作為CAR-T療法的合理腫瘤相關抗原(分別用於胃癌╱胰腺癌和肝細胞癌(或HCC))的公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account